

Under the Paperwork Reduction Act of 1995, no responses are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Date Submitted: March 11, 2005

(use as many sheets as necessary)

Complete if Known

Application Number Unassigned 10/527664  
Filing Date 03/11/2005  
First Named Inventor Christophe de ROMEUF et al.  
Group Art Unit Unassigned 1644  
Examiner Name Unassigned Chun Dahle  
Attorney Docket Number 065691-0389

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
/C.D./	A1	6,180,377	B1	BODMER et al.	01/30/2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A2	WO	01/77101	A1	OLADET et al.	10/10/2001		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>3</sup>
	A3	CARTON et al., "Therapeutic Activity of Humanized anti-CD20 Monoclonal Antibody and Polymorphism in IgGεc Receptor EpsilonB1/IIa Gene." Blood Vol. 98 No. 11 Part 1 November 16 2001 p. 602a XP-001193741, & 43" Annual Meeting of the American Society of Hematology, July 11, 2001.	
	A4	SHIELDS et al., "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIIIa and Antibody-Dependent Cellular Toxicity." Journal of Biological Chemistry, American Society of Biological Chemists, Vol. 277, No. 30, July 26, 2002, pp. 26733-26740, XP-002964542.	
	A5	SHINKAWA et al., "The Absence of Fucose But Not The Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-Type Oligosaccharides Shows The Critical Role of Enhancing Antibody-Dependent Cellular Cytotoxicity." Journal of Biological Chemistry, American Society of Biological Chemists, Vol. 278, No. 5, January 31, 2003, pp. 3466-3473, XP-002965857.	
	A6	VIDOVIC et al., "Selective Apoptosis of Neoplastic cells by the HLA-DR-Specific Monoclonal Antibody," Cancer Letters Vol. 128 No. 2 June 19 1998 pp. 127-135 XP-000857331	
	A7	WRIGHT et al., "Effect of Glycosylation on Antibody Function: Implications for Genetic Engineering," Trends in Biotechnology Elsevier Publications, Vol. 15 No. 1 1997, pp. 26-32, XP-004016809.	

Examiner Signature /Chun Dahle/ Date Considered 07/17/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.